{"log_id": 3918823125793431987, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0, "average": 0.999176, "min": 0.998806}, "location": {"width": 69, "top": 266, "height": 26, "left": 208}, "words": "【禁忌】"}, {"probability": {"variance": 5e-06, "average": 0.997747, "min": 0.992059}, "location": {"width": 355, "top": 311, "height": 34, "left": 239}, "words": "对活性成分和任何赋形剂成分过敏者禁用"}, {"probability": {"variance": 1e-06, "average": 0.999166, "min": 0.996774}, "location": {"width": 109, "top": 403, "height": 25, "left": 205}, "words": "【注意事项】"}, {"probability": {"variance": 4e-06, "average": 0.998593, "min": 0.99226}, "location": {"width": 257, "top": 450, "height": 32, "left": 198}, "words": "在肾功能损害的患者中的使用"}, {"probability": {"variance": 0.000578, "average": 0.992036, "min": 0.873035}, "location": {"width": 786, "top": 496, "height": 46, "left": 236}, "words": "由于缺乏关于雷奈酸锶治疗重度肾功能损害患者的骨安全性方面的资料,不建议本品用于肌"}, {"probability": {"variance": 0.000284, "average": 0.991629, "min": 0.942448}, "location": {"width": 168, "top": 543, "height": 25, "left": 196}, "words": "酐清除率小于30ml"}, {"probability": {"variance": 0.001917, "average": 0.988168, "min": 0.745433}, "location": {"width": 617, "top": 546, "height": 41, "left": 405}, "words": "的患者(详见【药代动力学】)。与临床实践管理规范相一致,建议慢性肾"}, {"probability": {"variance": 0.000248, "average": 0.993926, "min": 0.926103}, "location": {"width": 826, "top": 586, "height": 46, "left": 194}, "words": "功能损害的患者定期监测肾功能。可能进展成重度肾功能损害的患者是否继续使用本品,应当在个"}, {"probability": {"variance": 0, "average": 0.999314, "min": 0.998497}, "location": {"width": 181, "top": 632, "height": 29, "left": 194}, "words": "案的基础上进行考虑"}, {"probability": {"variance": 4.2e-05, "average": 0.994792, "min": 0.983732}, "location": {"width": 78, "top": 724, "height": 24, "left": 193}, "words": "静脉血栓"}, {"probability": {"variance": 0.008504, "average": 0.971503, "min": 0.461061}, "location": {"width": 787, "top": 770, "height": 45, "left": 230}, "words": "在Ⅲ期安慰剂对照研究中,雷奈酸锶的治疗与静脉血栓(VTE)包括肺静脉血栓的年发生率升"}, {"probability": {"variance": 0.001741, "average": 0.982191, "min": 0.751582}, "location": {"width": 826, "top": 813, "height": 49, "left": 189}, "words": "高有关(详见【不良反应】)。尚不清楚其中的原因。具有高VTE危险性的患者包括有VTE既往史"}, {"probability": {"variance": 0.004033, "average": 0.979135, "min": 0.689167}, "location": {"width": 825, "top": 860, "height": 48, "left": 190}, "words": "的患者,应当谨慎使用本品。当治疗高危险性的患者,或VTE危险性增高的患者,S应当特别注意"}, {"probability": {"variance": 0.005588, "average": 0.975397, "min": 0.674017}, "location": {"width": 416, "top": 906, "height": 36, "left": 191}, "words": "VTE的可能症状和体征,并采取适当的预防措施"}, {"probability": {"variance": 0, "average": 0.763663, "min": 0.763663}, "location": {"width": 61, "top": 959, "height": 29, "left": 788}, "words": "("}, {"probability": {"variance": 1.8e-05, "average": 0.99715, "min": 0.989735}, "location": {"width": 81, "top": 990, "height": 24, "left": 187}, "words": "皮肤反应"}, {"probability": {"variance": 0, "average": 0.883609, "min": 0.883609}, "location": {"width": 32, "top": 983, "height": 27, "left": 819}, "words": "4"}, {"probability": {"variance": 0.000509, "average": 0.989545, "min": 0.89279}, "location": {"width": 787, "top": 1027, "height": 48, "left": 226}, "words": "在本品使用中报道有严重的超敏反应综合征,特别是伴有嗜酸粒细胞增多和全身症状的药物"}, {"probability": {"variance": 0.004527, "average": 0.977512, "min": 0.582038}, "location": {"width": 825, "top": 1073, "height": 48, "left": 185}, "words": "疹( DRESS)),偶有致命性(详见【不良反应】) DRESS综合征典型表现为:皮疹、发热、嗜酸粒"}, {"probability": {"variance": 0.001862, "average": 0.986225, "min": 0.741992}, "location": {"width": 809, "top": 1119, "height": 48, "left": 184}, "words": "细胞增多和全身症状(如腺体疾病、肝炎、间质性肾炎、间质性肺病)。发病时间一般为3~6周"}, {"probability": {"variance": 6.9e-05, "average": 0.995956, "min": 0.958433}, "location": {"width": 728, "top": 1163, "height": 48, "left": 182}, "words": "大多数情况下停止使用本品和开始皮质激素治疗后结果良好,但恢复缓慢,已有报道"}, {"probability": {"variance": 1.9e-05, "average": 0.992568, "min": 0.986558}, "location": {"width": 58, "top": 1186, "height": 23, "left": 950}, "words": "些病例"}, {"probability": {"variance": 0.000893, "average": 0.989595, "min": 0.828911}, "location": {"width": 804, "top": 1210, "height": 46, "left": 182}, "words": "在停止皮质激素治疗后症状复发。应告知患者,当出现皮疹时应立即停止使用本品并告知医生"}, {"probability": {"variance": 0.000433, "average": 0.992685, "min": 0.908772}, "location": {"width": 568, "top": 1255, "height": 40, "left": 179}, "words": "因出现过敏反应或其他严重变态反应而停药的患者不应再使用本品"}, {"probability": {"variance": 2.6e-05, "average": 0.99637, "min": 0.985425}, "location": {"width": 197, "top": 1347, "height": 32, "left": 180}, "words": "与实验室检查相互作用"}, {"probability": {"variance": 0.000278, "average": 0.994272, "min": 0.894087}, "location": {"width": 786, "top": 1392, "height": 48, "left": 216}, "words": "锶干扰对血和尿钙浓度的比色法测定。因此在医疗工作中应当使用诱导耦合等离子体原子发"}, {"probability": {"variance": 5e-06, "average": 0.997804, "min": 0.991908}, "location": {"width": 511, "top": 1437, "height": 40, "left": 174}, "words": "射光谱法或原子吸收光谱法以确保精确地测定血和尿钙浓度"}, {"probability": {"variance": 1.6e-05, "average": 0.995199, "min": 0.990126}, "location": {"width": 64, "top": 1529, "height": 26, "left": 173}, "words": "赋形剂"}, {"probability": {"variance": 0, "average": 1, "min": 1}, "location": {"width": 171, "top": 1581, "height": 20, "left": 174}, "words": " osseor2g-s20110129-idi"}], "language": 3}